Literature DB >> 1891176

Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat.

G Cini Neri1, B Neri, M Bandinelli, M Del Tacca, R Danesi, R Riccardi.   

Abstract

The premise of this study is that mitochondrial lesions caused by anthracyclines lead directly to cardiotoxicity. We compared several biochemical parameters, including endogenous cellular respiration, adenosine and guanosine triphosphate levels, and 14C-amino acid incorporation, of rat hearts treated with doxorubicin and some of its derivatives, recent products of pharmacological research aimed at selecting less toxic antiblastic agents. In rats treated in vivo, we further examined the ultrastructural changes induced by anthracycline antibiotics in order to elucidate which biochemical parameters were consistent with the morphological lesions. Our data indicate that mitochondria are the target of the anthracycline effects and that oxygen uptake and nucleotide levels may be regarded as markers of the toxicity when evaluating new drugs before their clinical use. The lack of cytoplasmatic or endoplasmatic reticulum alterations may account for the failure of anthracyclines to affect amino acid incorporation. In any event, the rate of protein synthesis cannot serve as a marker of cardiac toxicity. In this context, epidoxorubicin and iododoxorubicin are two derivatives characterized by less cardiotoxic potential than doxorubicin and thus appear to be promising antiblastic agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1891176     DOI: 10.1159/000226952

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  7 in total

1.  The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice.

Authors:  H C Yen; T D Oberley; S Vichitbandha; Y S Ho; D K St Clair
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

Review 2.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin.

Authors:  R Danesi; N Bernardini; C Agen; M Costa; L Zaccaro; D Pieracci; G Malvaldi; M Del Tacca
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity.

Authors:  Ashish Gupta; Cory Rohlfsen; Michelle K Leppo; Vadappuram P Chacko; Yibin Wang; Charles Steenbergen; Robert G Weiss
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

6.  Effect of green tea extract on Doxorubicin induced cardiovascular abnormalities: antioxidant action.

Authors:  Leena Patil; R Balaraman
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.

Authors:  M A I Abou-El-Hassan; M J W E Rabelink; W J F van der Vijgh; A Bast; R C Hoeben
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.